UPDATE: Click here to order samples for your practice.
FOR PATIENTS WITH CHRONIC NONINFECTIOUS POSTERIOR UVEITIS
RETISERT® 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye to deliver corticosteroid therapy for approximately 2.5 years where it's needed¹
RETISERT® is surgically implanted into the posterior segment of the affected eye through pars plana incision¹
The implant consists of a tablet encased in a silicone elastomer cup containing a release orifice and a polyvinyl alcohol membrane positioned between the tablet and the orifice¹
Consider RETISERT® for patients who suffer from chronic noninfectious posterior uveitis who need long-term control of inflammation.¹
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full Prescribing Information for RETISERT®.
References: 1. RETISERT [Package Insert]. Rochester, NY: Bausch & Lomb Incorporated.; May 2019. 2. U.S. Food & Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000TOC.cfm Accessed October 4, 2017.
Indication and Important Safety Information
VISUDYNE is a registered trademark of Novartis AG used under license. © 2020 Bausch & Lomb Incorporated or its affiliates. RET.0035.USA.20
CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "Confirm" if you are a U.S. healthcare professional.